The proliferative activity of peripheral blood and bone marrow hematopoietic cells expressing protein Ki-67 in CML patients with different Sokal score and response to tyrosine kinase inhibitors therapy
The aim – to establish the prognostic significance of expression of Ki-67 protein by hematopoietic cells in peripheral blood and bone marrow of patients with CML in the formation of response to tyrosine kinase inhibitors therapy based on its collating with the Socal score.Methods. The expression of hematopoietic cells in peripheral blood and bone marrow of the proliferation marker Ki-67 of 79 CML patients was measured by flow cytometry in direct immunofluorescence test using monoclonal antibodies from a set of PE Mouse Anti-Human Ki-67 Set (BD Pharmingen, USA). Sokal score was determined in the debut of the disease. The recommendations from The European LeukemiaNet, update 2010, for the management of CML have used. Results. The expression of intranuclear protein in patients with intermediate Sokal score was more than three times higher compared to the low-risk group in peripheral blood and more than twice higher in bone marrow (p <0.05). In the high-risk group the number of cells that expressed Ki-67 was 4 times higher in the region of granulocytes and three times in the region of monocytes in peripheral blood compared to the low Socal risk group (p <0.05). In the bone marrow the expression of Ki-67 in patients with high Sokal risk group was twice higher than with low-risk Sokal (p <0.05). Conclusions. The relationship between the Socal score, the expression of Ki-67 and the response to imatinib therapy in CML patients treated with imatinib have been shown. An optimal response is achieved in patients with low Socal group and low intranuclear expression of Ki-67 protein, the worst results of therapy in patients was determined with high Sokal risk group and increased expression of Ki-67.
The choice of events to analyze the parameters of the front and side light scattering
How to cite this article:
Perekhrestenko T. The proliferative activity of peripheral blood and bone marrow hematopoietic cells expressing protein Ki-67 in CML patients with different Sokal score and response to tyrosine kinase inhibitors therapy . Pharma Innovation 2015;3(11):16-18.